Please provide your email address to receive an email when new articles are posted on . As with the low-concentration (50 mg/mL) version of Cyltezo (adalimumab-adbm ...
Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar SB5 and a high-concentration version. While 2023 is becoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback